1147531-06-3

Basic information

• Product Name: 2-((tert-butyldiMethylsilyloxy)Methyl)-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline
• Synonyms: 2-((tert-butyldiMethylsilyloxy)Methyl)-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline
• CAS NO: 1147531-06-3
• Molecular Formula: C₁₉H₃₄BNO₃Si
• Molecular Weight: 363
• Mol File: 1147531-06-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-((tert-butyldiMethylsilyloxy)Methyl)-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((tert-butyldiMethylsilyloxy)Methyl)-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(1147531-06-3)
• EPA Substance Registry System: 2-((tert-butyldiMethylsilyloxy)Methyl)-3-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)aniline(1147531-06-3)

Safety Data

• Hazardous Substances Data: 1147531-06-3(Hazardous Substances Data)

Usage

General Description

2-((tert-Butyldimethylsilyloxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is a complex organic compound with a silicon-containing group and a boron-containing group attached to an aniline molecule. The tert-butyldimethylsilyloxy group is a protecting group commonly used in organic synthesis to prevent unwanted reactions, while the dioxaborolane group is commonly used in cross-coupling reactions to form carbon-carbon bonds. The presence of these groups indicates that this compound is likely used as an intermediate in organic synthesis for the preparation of pharmaceuticals, agrochemicals, or materials. Its specific properties and uses would depend on the context of its synthesis and the intended reaction pathway.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 861106-91-4 (2-bromo-6-nitro-phenyl)-methanol 
• 1147531-02-9 ((2-bromo-6-nitrobenzyl)oxy)(tert-butyl)dimethylsilane 
• 1147531-04-1 3-bromo-2-[[tert-butyl(dimethyl)silyl]oxymethyl] aniline 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1147531-08-5 N-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4-(dimethylamino)benzamide 
• 1147530-03-7 N-[2-(tert-butyldimethylsilanyloxymethyl)-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]-4-dimethylaminobenzamide 
• 1361941-39-0 2-tert-butyl-5-((2-((tert-butyldimethylsilyloxy)methyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenylamino)methyl)thiazole-4-carboxylic acid 
• 1361941-38-9 methyl 2-tert-butyl-5-((2-((tert-butyldimethylsilyloxy)methyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenylamino)-methyl)thiazole-4-carboxylate 
• 1361941-37-8 methyl 2-tert-butyl-4-((2-((tert-butyldimethylsilyloxy)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)methyl)thiazole-5-carboxylate 

Relevant articles and documents

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

BTK protein kinase inhibitors

This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.